BidaskClub Lowers NuVasive (NASDAQ:NUVA) to Sell

BidaskClub lowered shares of NuVasive (NASDAQ:NUVA) from a hold rating to a sell rating in a research report sent to investors on Saturday morning, BidAskClub reports.

Several other analysts have also recently issued reports on NUVA. Piper Sandler cut their price target on shares of NuVasive from $90.00 to $75.00 and set an overweight rating on the stock in a report on Thursday, May 7th. Canaccord Genuity cut their price target on shares of NuVasive from $68.00 to $64.00 and set a buy rating on the stock in a report on Thursday, May 7th. Northland Securities began coverage on shares of NuVasive in a report on Thursday, June 25th. They issued a market perform rating and a $65.00 price target on the stock. JPMorgan Chase & Co. cut their price target on shares of NuVasive from $80.00 to $60.00 and set a neutral rating on the stock in a report on Monday, May 4th. Finally, Needham & Company LLC upgraded shares of NuVasive from a hold rating to a buy rating and set a $74.00 target price for the company in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $70.35.

NASDAQ NUVA opened at $54.35 on Friday. The company’s fifty day simple moving average is $59.92 and its 200-day simple moving average is $64.36. NuVasive has a 52 week low of $28.55 and a 52 week high of $81.91. The company has a current ratio of 1.35, a quick ratio of 0.94 and a debt-to-equity ratio of 0.54. The stock has a market cap of $2.64 billion, a P/E ratio of 47.26, a PEG ratio of 5.25 and a beta of 1.41.

NuVasive (NASDAQ:NUVA) last posted its earnings results on Wednesday, May 6th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.07. The business had revenue of $259.88 million for the quarter, compared to analysts’ expectations of $262.32 million. NuVasive had a net margin of 5.30% and a return on equity of 14.42%. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.53 earnings per share. On average, research analysts expect that NuVasive will post 0.73 EPS for the current fiscal year.

In other NuVasive news, President Matthew Link sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $67.00, for a total transaction of $201,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.97% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the stock. FDx Advisors Inc. acquired a new position in shares of NuVasive during the 1st quarter worth approximately $25,000. Altshuler Shaham Ltd increased its holdings in shares of NuVasive by 182.7% during the 4th quarter. Altshuler Shaham Ltd now owns 424 shares of the medical device company’s stock worth $33,000 after acquiring an additional 274 shares during the last quarter. HighMark Wealth Management LLC acquired a new position in shares of NuVasive during the 4th quarter worth approximately $38,000. Sowell Financial Services LLC increased its holdings in shares of NuVasive by 53.4% during the 1st quarter. Sowell Financial Services LLC now owns 1,091 shares of the medical device company’s stock worth $55,000 after acquiring an additional 380 shares during the last quarter. Finally, Westside Investment Management Inc. acquired a new position in shares of NuVasive during the 1st quarter worth approximately $75,000.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Story: What does a bar chart display?

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.